Egrifta · TH9507
FDA-approved GHRH analog — visceral fat reduction.
FDA
Approved
WADA
Banned
HALF-LIFE
~26 minutes
ROUTE
SubQ injection
SCHEDULE
Daily
In Plain English
FDA-approved GHRH analog — visceral fat reduction.
Status & Legality
NATTY?
Not NattyWADA banned substance. Tested athletes will fail.
FDA
ApprovedFDA approved for human use.
WADA
BannedOn WADA prohibited list. Use disqualifies in tested sports.
COMPOUNDING
Rx AvailableAvailable at licensed pharmacies with prescription.
PRESCRIBED
By prescriptionPhysicians can prescribe this compound legally.
ROUTE
SubQ injectionAdministration via subq injection.
Visceral fat reduction
HIV lipodystrophy
GH deficiency
Cognitive function
Tesamorelin is the only FDA-approved GHRH analog, approved specifically for HIV-associated lipodystrophy (excess visceral fat). It stimulates the pituitary to release GH, leading to visceral adipose tissue reduction. Research also shows improvement in cognitive performance in older adults and GH-deficient patients.
Joint/muscle pain
Injection site reactions
Fluid retention
Nausea
Glucose intolerance at high doses
Skipping IGF-1 monitoring — elevated IGF-1 is the key efficacy marker and the primary safety indicator for GH axis protocols
Expecting visceral fat results without dietary changes — tesamorelin reduces fat, but doesn't override a poor diet
Not monitoring glucose — tesamorelin can cause glucose intolerance at the full 2 mg dose, especially in those with metabolic risk
Glucocorticoids — significantly blunt the GHRH response; avoid combining
Insulin and diabetes medications — glucose management requires monitoring during GH elevation
Thyroid hormones — adequate thyroid function is needed for the full GH axis response; test thyroid before starting
Tesamorelin is the most evidence-backed GHRH for visceral fat reduction — the only FDA-approved GHRH analog in existence. If reducing visceral fat is the primary goal, 2 mg/day for 6+ months with IGF-1 monitoring is the gold standard protocol. Significantly more targeted than generalist GH secretagogue approaches.
Stats
Sources & Studies
Falutz J. et al., N Engl J Med, 2010